Skip to main content

About Bard Australia

For more than 100 years, C. R. Bard, Inc. has been developing innovative medical devices that meet the needs of healthcare professionals and patients. From a one man shop in 1907 to a global leader in the medical device industry we are committed to enhancing the lives of people around the world.

Prior to 1991, a third party distributor was used to sell Bard products within Australia. Over time, the business grew and in 1991 the decision was taken to sell direct in Australia and a local legal entity was established. Bard’s business in Australia has continued to flourish since that time.

Our Mission

To advance lives and the delivery of healthcare by profitably developing, manufacturing and marketing value-driven products which meet the quality, integrity, service, and innovation expectations of our customers while providing opportunities for our employees.  As a result, we will optimize shareholder value and be a respected worldwide health care company.

Core Values and Guiding Principles

Bard's Guiding Principles were created to supplement our four Core Values of Quality, Integrity, Service, and Innovation. These guiding principles have been identified in order to express how we want to conduct business today and in the future.

Passion for our Work

1. Passion For Our Work

We focus on improving the lives of patients who require our products and services. We are proud of our long history of achieving this goal and firmly believe that our work makes a difference. We are relentless in our efforts to provide the highest quality products and services.

Be Indispensible

2. Be Indispensable To Our Customers

We believe in anticipating and exceeding customer expectations, and in eliminating any barriers to meeting our customers' needs. We place high value on being the company of choice for providers and other clinicians wanting to transform their inventive concepts into valued products and services to treat their patients successfully.

Creative Thinking

3. Foster Creative Thinking

We value fresh, resourceful, and creative ideas that enable us to achieve our mission, set standards, and win in the market place. By fostering an open and flexible environment, we encourage inventive concepts and solutions from our employees and from inventors and physicians, who have ideas for new medical devices or services.


4. Highest Ethical Behavior

We believe that fundamental honesty and ethical behavior are at the core of who we are and what we do. We demonstrate our respect for each other, our shareholders, customers, and communities by honoring our commitments and being reliable and trustworthy. 


5. Demonstrate Ownership and Pride 

We take pride in our work, act with conviction, and feel accountable to each other, our company, customers, and shareholders. As an integral part of C. R. Bard, Inc., we involve each other appropriately and openly communicate so we can all add value to and share in C. R. Bard, Inc.’s success.

Leadership by Example

6. Leadership by Example

We are committed to the importance of leadership and initiative. We believe in supporting employees with the courage and knowledge to establish new standards and the skill to motivate others to positive action. We expect leaders to communicate effectively, to remove obstacles, and to provide the tools we all need to achieve excellence.


7. Play to Win 

We believe a collective competitive spirit, guided by our values, is key to market leadership. We play to win and, therefore, set challenging and aggressive goals that provide focus and value results over activity.[4]


8. Be Open and Inclusive

We are open to new ideas, we respect the diverse backgrounds and opinions of others and we invite people to be themselves at work. We foster an inclusive culture where we all work together across functional and geographic boundaries and share diverse perspectives and capabilities to deliver superior outcomes for our business, our shareholders, our customers and the patients we serve. We are a closely aligned, globally diverse company.


A Long History of Technological Innovation

Charles Russell Bard, founder of C.R. Bard


Charles Russell Bard (pictured) was an American importer of French silks. In 1907, he begins importing Gomenol in New York City.


Gomenol, a European cure-all, helped relieve Mr. Bard's urinary discomfort from tuberculosis.


C. R. Bard, Inc. is formally incorporated.


Bard publishes its first product catalog.

John F. Willits and Edson L. Outwin


Charles Russell Bard sells business to John F. Willits (pictured left), Sales Manager, and Edson L. Outwin (pictured right), Accountant, for $18,000.

Harris L. Willits


Harris L. Willits (pictured) joins the Bard staff as a sales representative.

Charles Russell Bard, founder of C.R. Bard, Inc.


Company founder Charles Russell Bard dies.

Davol Rubber Company historic illustration and patent application


Davol Rubber Company of Providence, Rhode Island begins to manufacture the Foley catheter. Bard becomes the exclusive distributor for the Foley catheter and other Davol latex catheters.

Pictured: The Davol Rubber Company in 1934, and an illustration accompanying Davol Rubber Company's 1935 patent application for a rubber catheter invented by Paul A. Raiche, an experimental engineer.


Norman Jeckel develops the first American woven catheter and the machinery to manufacture it. He establishes the U.S. Catheter & Instrument Corporation (USCI) in Glens Falls, New York. Bard begins to distribute Jeckel's new catheter.


Harris L. Willits becomes a member of the Board of Directors.


Bard moves from New York City into a new building in Summit, New Jersey, and in 1949 the first Bard sales meeting is held at headquarters with representatives from Davol & USCI.

Dr. DeBakey


Dr. DeBakey (pictured) develops the first arterial prosthesis.

Harris L. Willits


Harris L. Willits (pictured) is elected President of Bard.

Edson L. Outwin, James Vassar, Harris Willits, and Edson S. Outwin at Canoe Brook Country Club in 1957


Bard celebrates its 50th anniversary, marking five decades of dedication to the medical profession. Pictured left to right: Edson L. Outwin, James Vassar, Harris Willits, and Edson S. Outwin at Canoe Brook Country Club in December 1957.

1958 Bardex Foley catheter advertisement


Bard introduces a pre-sterilized packaged Foley catheter and has a sterilizer built to start handling in-plant sterilization. Pictured: A 1958 Bardex Foley catheter advertisement explains how sterilized, packaged products can save customers time and money and also provide convenience since they are ready for instant use. 

Historical photo of C.R. Bard, Inc. headquarters in Murray Hill, NJ


Bard moves into a new one-story 50,000 square foot building in Murray Hill, New Jersey (pictured). The larger facility allowed the company to centralize its offices.

BARD employee at Glens Falls, NY plant inspecting coronary catheters


Bard begins to extend its efforts beyond the urology market into cardiology, radiology and anesthesiology.

Pictured: A Bard employee at the Glens Falls, New York, plant inspects coronary catheters produced by Bard's USCI Cardiology and Radiology Division.

Medical supply storage at BARD’s Bridgewater, NJ location and in-house sterilization operations


Bard establishes its first in-house manufacturing operation — producing the molding and assembling of medical plastic tubing.
Pictured, left: Sterile and disposable medical supplies are stacked high at Bard's plant in Bridgewater, New Jersey, in the early 1960s.
Pictured, right: The introduction of in-house sterilization operations in 1964 greatly expanded Bard’s manufacturing capabilities since laborsaving devices such as pre-sterilized hospital supplies had become a necessity rather than a luxury in the 1960s.


Bard announces a 3-for-2 stock split.

Roland F. Simons


Harris L. Willits becomes Chairman of the Board. Roland F. Simons (pictured) is elected President. Simons was instrumental in increasing Bard's research and development programs throughout the 1960s.


Bard and USCI merge, cementing a 25 year association.


Bard builds a 100,000 square foot plant in Covington, Georgia, geographically expanding its manufacturing and warehousing operations.


Bard announces a 2-for-1 stock split.


J. Wendell Crain is elected President.


Bard's capital stock is listed and traded on the New York Stock Exchange under the symbol "BCR".

Technicians at BARD subject samples of urological products to USP sterility testing


Bard builds a 172,000 square foot manufacturing plant at the Murray Hill, New Jersey location.
Pictured: Technicians at Bard's New Jersey facilities subject samples of urological products to United States Pharmacopeia (USP) sterility testing, upholding the company's commitment to the highest product quality.

Harris L. Willits


Harris L. Willits is elected to honorary membership in the Medical Surgical Manufacturers Association, a distinction awarded only six other people.

Jay Bhaat, manager of BARD Japan in 1977, speaks at a USCI seminar; BARD’s Medicon unit


Bard joins with Kobayashi Pharmaceutical Company, Ltd. of Japan in establishing what is now known as Medicon, Inc., to import and market Bard products in Japan and form new joint ventures with international manufacturers.

Pictured, left: Jay Bhatt, Bard's Japan manager in 1977, speaks at a USCI Division seminar in Tokyo, Japan.

Pictured, right: With new leadership, Bard's Medicon unit saw fresh opportunities for business as Japan changed to diagnosis-based reimbursement. Indeed, sales grew by 27 percent in 2004. Pictured from left to right are K. Minato, Y. Sakai, and T. Kashiwagi.


Bard announces a 2-for-1 stock split.

BARD inspector in Santa Ana, CA examines components of blood oxygenators


Bard acquires the William Harvey Research Corporation, expanding cardiopulmonary products for open-heart and bypass surgery.
Pictured: An inspector at the Santa Ana, California, plant examines components of William Harvey blood oxygenators used for cardiothoracic surgery.


Robert H. McCaffrey is elected Director and President.

Robert H. McCaffrey, Harris Willits and George Maloney


Robert H. McCaffrey is elected Chairman of the Board and Chief Executive Officer. George T. Maloney is elected President and Chief Operating Officer.
Pictured, from left to right: Over the years, Robert McCaffrey, Harris Willits, and George Maloney developed a friendly corporate culture, which many Bard employees welcomed with gratitude.


Harris L. Willits is elected Honorary Chairman.

Doctor using BARD’s USCI catheter system


Bard obtains the exclusive rights to manufacture and market the Gruntzig catheter, a balloon-tipped angioplasty catheter giving surgeons a safer and less costly alternative to open-heart surgery.
Pictured: Using one of Bard's USCI catheter systems, a doctor prepares for an angioplasty procedure in a catheterization laboratory.

Historical photography of Davol, Inc. location


After a 46-year association, Bard acquires Davol Inc. (pictured), with its Foley catheter manufacturing facilities in Moncks Corner, South Carolina and Clacton-On-Sea, England.


Bard announces a 3-for-2 stock split.


Bard sets up manufacturing plant in Nogales, Mexico.


Bard  acquires Evermed, creating the platform for the Bard Access Systems franchise.


A joint venture, Bard Bio-Spectrum Pty. Ltd., is created in Australia.


Bard announces a 2-for-1 stock split.

Laboratories Bard in Paris; a cardiologist in the lab of Policlinico Umberto


Bard Europe is formed by merging Bard UK/Europe with USCI International.

Pictured, left: A cardiologist in the laboratory of Policlinico Umberto in Rome, Italy, examines Bard Simplus and Probe angioplasty catheters in 1988. Courtesy of John Zoiner Photography. 
Pictured, right: The headquarters of Laboratories Bard in the Paris suburb of Gentilly, France. 

Edward A. Leskanic, David W. Prigmore, and Laurence E. Lindars. Seated: George A. Davis, William G. Little, Terence C. Brady Jr., George T. Maloney, and Robert H. McCaffrey


Bard's 1985 Management Executive Committee guided the company's divisions to operate as entrepreneurial units and remain organized around market specialization. Pictured from left to right, standing: Edward A. Leskanic, David W. Prigmore, and Laurence E. Lindars. Seated: George A. Davis, William G. Little, Terence C. Brady Jr., George T. Maloney, and Robert H. McCaffrey. Courtesy of Bill Ray Photography.

George T. Maloney greets visitors at C.R. Bard’s annual meeting


George T. Maloney (pictured, greeting visitors at Bard’s annual meeting) is elected President and Chief Executive Officer. His friendly and personable nature, as well as his problem-solving skills and sharp mind, earned him a solid reputation for more than three decades with the company.

An I.V. nurse discusses cathether placement at a patient’s bedside with BARD employees


Bard acquires Catheter Technology Corporation, Salt Lake City, Utah, strengthening Bard's position in the vascular access devices market. This becomes the divisional headquarters for Bard Access Systems, Inc. in 1991.
Pictured: An I.V. nurse at Christ Hospital in Cincinnati, Ohio, discusses catheter placement at a patient's bedside with Bard Access Systems employees.


Bard Electrophysiology Division is formed.

George T. Maloney


George T. Maloney (pictured) is elected Chairman of the Board and Chief Executive Officer.


Bard Bio-Spectrum Pty. Ltd. becomes Bard Australia.


Harris L. Willits, Honorary Chairman, dies.


William Longfield (pictured) is elected President and Chief Executive Officer.


Bard acquires Angiomed AG (biliary stent).

BARD Corporate Healthcare Services logo


Corporate Healthcare Services organization is established.


William Longfield is elected Chairman of the Board.


Bard acquires IMPRA, Inc. (vascular prosthetics).

A quality assurance auditor at Bard FiberOptic Technologies; the BARDEX Lubricath Foley catheter


Bard Medical Division is formed. 

Pictured, left: Bard FiberOptic Technologies in Ann Arbor, Michigan, which manufactured high-tech urological monitoring devices using fiber optics, added to the company's technological revolution in the late 1990s. Here, quality assurance auditor Donna Reese performs an inspection.  

Pictured, right: The BARDEX® Lubricath Foley catheter is a late 1990s update of the Foley catheter, Bard's trademark product.

A BARD employee conducts flow tests on PDLC


Bard enters joint venture agreement with Pacific Healthcare in Taiwan. Bard opens sales offices in China, Korea and Singapore.
Pictured: At Bard, new product development and incremental product improvement is a continuous process. Bard employee Hong le Nguyen conducts flow tests on PDLC.


Bard divests USCI cardiology division, cardiac assist & cardiopulmonary business units.

A BARD employee assembles the rod for a dual lumen wing retainer


Bard acquires Dymax Inc. an ultrasound technology for placing catheters. The 1994 Vas-Cath acquisition helped Bard expand its dialysis catheter and peripheral balloon angioplasty catheter product lines.
Pictured: Bard employee Lena Diaz assembles the rod for a dual lumen wing retainer.


Bard acquires the assets of Surgical Sense, Inc. and its Kugel® patch product line.

Timothy M. Ring and John Weiland


Timothy M. Ring (pictured, left) is elected Chairman of the Board and Chief Executive Officer. John Weiland (pictured, right) is elected President and Chief Operating Officer. Both were groomed by predecessor William Longfield to continue growing Bard in the 21st century. In their first full year running the company, net sales grew by 13 percent in constant currency.
Courtesy of Gloria Baker Photography.

Luminexx vascular stent; Ventralex hernia patch


Bard Peripheral Vascular subsidiary is formed. Pictured top: Luminexx™ vascular stent


Bard acquires vacuum-assisted biopsy device technology from Biomedical Instruments and Products GmbH.

Successful BARD patient Herman Herndon, treated with ProSeed Brachytehrapy service


Bard acquires SourceTech Medical, L.L.C., an iodine radioactive isotope seed business for Brachytherapy
Pictured: Hunter Herndon, of Midlothian, Virginia, buffs the wheel of his vintage 1934 Ford Coupe. Herndon was able to quickly return to his normal activities after undergoing treatment for prostate cancer with Bard's ProSeed® Brachytherapy service, which places tiny radioactive seeds guided by ultrasound into the prostate gland.
Courtesy of Gloria Baker Photography.


Bard acquires assets of ONUX Medical and its Salute® fixation system for hernia and soft tissue repair.

BARD worldwide operations team


Bard announces 2-for-1 stock split.
In 2003, Bard's worldwide operations team spearheaded improvements that increased profit margins by 3.2 percentage points. Pictured clockwise from top left are Mark Walaska, staff vice president of manufacturing; Frank Maloit, staff vice president for corporate procurement; Scott Mummert, director for operational excellence; Kevin Phoenix, director of facilities; John Moran, staff vice president for manufacturing projects; Ted Doorley, staff vice president for manufacturing; and Joe Cherry, vice president of operations.
Courtesy of Gloria Baker Photography.


Bard acquires assets of Genyx Medical, including the TegressT implantable bulking agent for the treatment of stress urinary incontinence.


Bard acquires Venetec International, Inc., manufacturer of the StatLock® line of catheter securement devices.

BARD 100th anniversary seal


Bard celebrates 100 year milestone.

Bard LifeStent


Bard acquires LifeStent® (pictured) from Edwards Lifesciences which is marketed by Bard’s Peripheral Vascular Division, Tempe Arizona.


Bard receives FDA PMA approval of LifeStent® for SFA (superficial femoral arteries) indication.


In the largest acquisition to date, Bard acquires SenoRx, Inc., providing Bard leadership products across all breast biopsy and marker segments.

Medivance Arctic Sun


Bard acquires Medivance, Inc., the market leader in the field of therapeutic hypothermia. Medivance's Arctic Sun® family of products provides clinicians with a powerful technology to effectively manage patient temperature in a non-invasive manner.

Lutonix transliminal angioplasty (PTA) balloon


Bard acquires Lutonix, Inc., developer of a drug-coated percutaneous transluminal angioplasty (PTA) balloon. Lutonix is the first to conduct the only investigational device exemption (IDE) trial approved by the FDA using drug-coated balloons for the treatment of peripheral arterial disease.

Neomend logo


Bard acquires privately-held Neomend, Inc., a leading developer and supplier of sprayable surgical sealants and anti-adhesion products.  This merger significantly expands the business opportunities for Bard surgical specialties in the Davol subsidiary.

Medafor Arista MPH hemostat


Bard Acquires Medafor, Inc., a leading developer and supplier of plant based hemostatic agents. Medafor’s Arista® MPH Hemostat, is indicated as an adjunctive hemostatic agent to control bleeding when conventional means are ineffective or impractical. The acquisition expands the business opportunities for Bard’s surgical specialties in its Davol subsidiary.

BARD electrophysiology logo


Bard divests Electrophysiology business and sells certain assets to Boston Scientific Corporation. 


Bard acquires Rochester Medical, Inc., a leading developer and supplier of silicone urinary incontinence and urine drainage products. The merger represents a compelling strategic fit that enhances Bard’s position in the global urology homecare market.

Lutonix 035 drug coated balloon


The Lutonix® 035 Drug Coated Balloon is the first FDA-Approved Drug Coated Balloon available in the U.S. for the treatment of Femoropopliteal Occlusive Disease. The Lutonix® 035 DCB is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD) in the femoropopliteal arteries.

XenMatrix AB surgical graft antibacterial-coated regenerative collagen matrix


XENMATRIX™ AB Surgical Graft Antibacterial-Coated Regenerative Collagen Matrix is the first antibacterial-coated, non-crosslinked porcine dermal graft proven to inhibit the graft colonization of MRSA, E. coli, and other bacteria in preclinical models.1,2  It uses a combination of well-characterized antibiotics, Rifampin and Minocycline, to offer an unmatched level of graft protection in challenging ventral hernia repair.
1. IMS Data, Q2 2014, 550K search,  
2. Preclinical data on file; results may not correlate to clinical performance.


Bard acquires full ownership of its joint venture, Medicon, Inc., in Japan.


Bard acquires Liberator Medical Holdings, Inc.  Liberator is a direct-to-consumer distributor of medical products classified as Durable Medical Equipment (DME).